ColoSense
Commercial- Indications
- Colorectal cancer screening
Company intelligence / Profile preview
Geneoscopy has developed ColoSense, an FDA-approved, noninvasive at-home stool-based diagnostic test for colorectal cancer that leverages their proprietary seRNA biomarker platform. Clinical results demonstrate high sensitivity and specificity for early CRC detection. The company is also advancing diagnostics for IBD with ongoing collaborations to validate its technology in therapy selection and monitoring.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Geneoscopy.